Search Results for: ustr

KEI comments at July 25, 2017 civil society stakeholder forum at the 19th round of the RCEP negotiation

Posted on by James Love

These are the notes I used when providing the KEI comments at the July 25, 2017 civil society stakeholder forum at the 19th round of the RCEP negotiation.

My name is James Love. I work for Knowledge Ecology International, an NGO that focuses on the social aspects to the production, management and control of knowledge goods. I am also a member of the board of directors of the Union for Affordable Cancer Treatment.

The IP Chapter is complex, and in the time allocated, I will discuss five issues.

Continue Reading →

House Appropriations rejects Kaptur amendment (allow competition for gov funded drugs if prices higher than reference countries)

Posted on by Kim Treanor

On 19 July 2017, Rep. Marcy Kaptur (D-OH) introduced an amendment at the markup in the U.S. House Appropriations Committee of the FY2018 State and Foreign Operations, Labor, Health and Human Services Appropriations bill that would direct the Department of Health and Human Services to use its authority to break patent monopolies for government-funded inventions priced higher in the U.S. than seven other high-income countries.

Continue Reading →

Senate Armed Services Committee directive on use of Bayh-Dole rights for DoD funded drugs

Posted on by Kim Treanor

The report of the Senate Armed Services Committee on the National Defense Authorization Act of 2018, S. 1519, published July 10, 2017, includes a directive that links exclusive patent rights to the prices of drugs, vaccines and other medical technologies that are based upon DoD-funded inventions.

The text of the directive, approved unanimously by the full Senate Armed Services Committee, is as follows:

Continue Reading →

Groups, individuals write to Senator Wyden, appalled at pressure on India over drug patents

Posted on by James Love

On June 23, 2017, Senators Orrin Hatch (R-UT) and Ron Wyden (D-OR) and Representatives Kevin Brady (R-TX) and Richard Neal (D-MA) wrote to President Trump about “trade and investment barriers” in India. The four members of Congress are respectively the chair and ranking members of the Senate Finance and the House Ways and Means Committee.

Continue Reading →

Uncategorized

Brussels Principles on Medication Sales over the Internet

Posted on by Andrew Goldman

On March 31st, KEI joined Prescription Justice, EFF, and Public Citizen at RightsCon 2017 to discuss the issues of sales of medication over the Internet. I was in attendance on KEI’s behalf; Gabe Levitt represented Prescription Justice; Jeremy Malcolm presented for EFF; and Burcu Kilic was there for Public Citizen. It was one of the few panels at RightsCon dedicated to medicines/health.

After the session, the panelists convened to draft an agreement on a series of overarching principles that may help guide policy and shape the conversation.

Continue Reading →

Six Senators Call on Army to Hold Public Hearing on Proposed Exclusive License of Zika Vaccine to Sanofi

Posted on by Andrew Goldman

Today, six Senators, including Sen. Durbin (D-IL), Sen. Sanders (I-VT), Sen. Markey (D-MA), Sen. Brown (D-OH), Sen. Blumenthal (D-CT), and Sen. Angus King (I-ME), sent a letter to Acting Secretary of the Army Robert Speer requesting a public hearing on the proposed exclusive license of a federally-funded Zika vaccine to the French multinational, Sanofi, and saying that “it is imperative that any forthcoming vaccine is accessible and affordable for all, especially given the significant taxpayer investment to date.”

Continue Reading →

Uncategorized

HRC35: Human Rights Council adopts Right to Health Resolution

Posted on by Thiru

The United Nations Human Rights Council (HRC) convened its 35th session from 6 June 2017 to 23 June 2017. During HRC35 (which took place in Room XX of the UN Palais des Nations in Geneva), a group of 21 countries tabled a resolution entitled, “The right of everyone to the enjoyment of the highest attainable standard of physical and mental health in the implementation of the 2030 Agenda for Sustainable Development”. Continue Reading →

June 2017 – WTO TRIPS Council – Statement of Brazil on IP and the Public Interest – Compulsory Licensing

Posted on by Thiru

As reported by Knowledge Ecology International (KEI), on 6 June 2017, the World Trade Organization (WTO), published a paper tabled by Brazil, China, Fiji, India, and South Africa, entitled “Intellectual Property and the Public Interest.” In their communication (IP/C/W/630), the proponents called for a series of discussions at the WTO TRIPS Council on Intellectual Property and the Public Interest. Continue Reading →

FOIA documents: In 2015 Novartis asked U.S. Dept of Commerce to Pressure Colombia Against Compulsory License on Glivec

Posted on by Andrew Goldman

In February 2016, KEI submitted a FOIA to USTR requesting “all correspondence and notes sent internally by the Office of the US Trade Representative as well as with Colombian government officials, other foreign government officials, and non-governmental persons or entities regarding efforts in the government of Colombia to issue compulsory licenses on medical technologies. Continue Reading →

WHO donors in 2016 (US, Gates Foundation, UK, GAVI Alliance, Japan): Setting the agenda for global public health?

Posted on by Thiru

In the run up to the 70th World Health Assembly (22 May 2017 – 31 May 2017), the World Health Organization prepared a document (A70/INF./4, 16 May 2017) entitled, Voluntary contributions by fund and by contributor, 2016. Total voluntary contributions to WHO in 2016 amounted to $1,717,219,177 which represented a dip from the 2015 figure of $1,836,970,206.

Here is a non-exhaustive list detailing the sources of voluntary contributions to WHO and the size of their respective contributions in 2016.

Continue Reading →

Uncategorized